Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904926 · ClinicalTrials.gov registry record
Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults
A clinical trial, sponsored by NMD Pharma A/S.
- Completed
- Registry status
- 19
- Enrollment target
NCT04904926: Completed study, sponsored by NMD Pharma A/S.
NCT04904926 is a clinical trial that has completed, run by NMD Pharma A/S. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04904926 has completed, sponsored by NMD Pharma A/S.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
Sarcopenia is a condition characterised by age-related loss of muscle mass and function. Factors affecting the strength of muscle contraction independent of mass, such as neuromuscular junction (NMJ) transmission, are increasingly suspected as important contributors to the development of age-related physical disability. The group of investigators leading the current study, have recently demonstrated NMJ transmission deficits in aged mice, but whether this translates in older human individuals is not known The primary aim is to assess whether clinically meaningfull muscle weakness is associated with NMJ transmission deficits in older human individuals with clinically meaningfull muscle weakness. The secondary aim is to assess whether NMJ transmission deficits correlate with different measures of functional capacity to inform future trials of the most appropriate choice of tests.
Primary Outcome
sfEMG of the vastus lateralis will be performed to ascertain NMJ transmission at a minimum of 30 synapses per participant.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2021-09-22 |
What the finished NCT04904926 record still lists
NCT04904926 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04904926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04904926 about?
NCT04904926 is a clinical study titled "Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults". Sarcopenia is a condition characterised by age-related loss of muscle mass and function. Factors affecting the strength of muscle contraction independent of mass, such as neuromuscular junction (NMJ) transmission, are increasingly suspected as important contributors to the development of age-related...
What is the current status of trial NCT04904926?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2021-03-16. Estimated completion is 2021-09-22.
Who is sponsoring clinical trial NCT04904926?
This trial is sponsored by NMD Pharma A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI